PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for the treatment of rare disorders. The company offers Translarna (ataluren) for the treatment of nonsense mutation Duchenne muscular dystrophy in ambulatory patients; and Emflaza (deflazacort) for treating Duchenne muscular dystrophy. It is developing Translarna, which is in Phase II clinical study for the treatment of nonsense mutation aniridia and nonsense mutation Dravet syndrome/CDKL5; and RG7916 for the treatment of patients with spinal muscular atrophy, as well as PTC596, an orally bioavailable and potent small molecule that has completed Phase I study, which targets solid tumor cell populations by reducing the activity and amount of BMI1. The company has collaborations with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., and the Spinal Muscular Atrophy Foundation to develop and commercialize compounds identified under its spinal muscular atrophy sponsored research program; research collaboration with Massachusetts General Hospital for the treatment of rare genetic disorders resulting from pre-mRNA; and research collaboration with CHDI Foundation, Inc. to discover and develop small-molecule therapeutics for Huntington's disease. PTC Therapeutics, Inc. was founded in 1998 and is headquartered in South Plainfield, New Jersey.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone908-222-7000
Debt
Current Ratio2.73
Quick Ratio2.61
Price-To-Earnings
Sales & Book Value
Annual Sales$194.39 million
Price / Sales8.92
Price / Cash FlowN/A
Price / Book9.12
Profitability
Net Income$-79,000,000.00
Net Margins-30.61%
Return on Assets-11.61%
Miscellaneous
Employees373
OptionableOptionable
PTC Therapeutics (NASDAQ:PTCT) Frequently Asked Questions
What is PTC Therapeutics' stock symbol?
PTC Therapeutics trades on the NASDAQ under the ticker symbol "PTCT."
How were PTC Therapeutics' earnings last quarter?
PTC Therapeutics, Inc. (NASDAQ:PTCT) issued its quarterly earnings data on Monday, November, 5th. The biopharmaceutical company reported ($1.06) EPS for the quarter, missing analysts' consensus estimates of ($0.40) by $0.66. The biopharmaceutical company earned $53.59 million during the quarter, compared to analyst estimates of $70.56 million. PTC Therapeutics had a negative net margin of 30.61% and a negative return on equity of 27.95%. The business's quarterly revenue was up 28.0% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.82) earnings per share. View PTC Therapeutics' Earnings History.
When is PTC Therapeutics' next earnings date?
What price target have analysts set for PTCT?
8 Wall Street analysts have issued twelve-month price objectives for PTC Therapeutics' shares. Their predictions range from $31.00 to $61.00. On average, they anticipate PTC Therapeutics' stock price to reach $47.7143 in the next year. This suggests a possible upside of 36.8% from the stock's current price. View Analyst Price Targets for PTC Therapeutics.
What is the consensus analysts' recommendation for PTC Therapeutics?
8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for PTC Therapeutics in the last year. There are currently 3 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for PTC Therapeutics.
What are Wall Street analysts saying about PTC Therapeutics stock?
Here are some recent quotes from research analysts about PTC Therapeutics stock:
- 1. According to Zacks Investment Research, "PTC Therapeutics, Inc. is a biopharmaceutical company. It is focused on the discovery and development of orally administered, small-molecule drugs for genetic disorders, oncology and infectious disease. PTC Therapeutics, Inc. is based in South Plainfield, United States. " (1/9/2019)
- 2. Cantor Fitzgerald analysts commented, "We met with full PTCT management this morning after their press release and are highlighting the key points here. We think value for and AADC still remain unappreciated at the current valuation. Longer term their Agilis acquisition could give broader access to gene therapy platform sales. The Company is focusing on long term revenue diversification potential beyond Translarna and Emflaza with Akcea and gene therapy programs." (1/7/2019)
- 3. William Blair analysts commented, "We show reported earnings, our estimates, and consensus in exhibit 1." (11/6/2018)
Has PTC Therapeutics been receiving favorable news coverage?
Media coverage about PTCT stock has been trending somewhat negative this week, InfoTrie Sentiment Analysis reports. The research group ranks the sentiment of press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. PTC Therapeutics earned a daily sentiment score of -1.6 on InfoTrie's scale. They also gave news headlines about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the company's share price in the near future.
Who are some of PTC Therapeutics' key competitors?
Some companies that are related to PTC Therapeutics include SAGE Therapeutics (SAGE), Perrigo (PRGO), Dr.Reddy's Laboratories (RDY), Amarin (AMRN), GALAPAGOS NV/S (GLPG), Alkermes (ALKS), United Therapeutics (UTHR), Catalent (CTLT), FibroGen (FGEN), TESARO (TSRO), GW Pharmaceuticals PLC- (GWPH), Amneal Pharmaceuticals (AMRX), Horizon Pharma (HZNP), Array Biopharma (ARRY) and Taro Pharmaceutical Industries (TARO).
Who are PTC Therapeutics' key executives?
PTC Therapeutics' management team includes the folowing people:
- Dr. Stuart W. Peltz, Co-Founder, CEO & Exec. Director (Age 58)
- Dr. Allan Steven Jacobson, Co-Founder, Chairman of Scientific Advisory Board & Director (Age 72)
- Ms. Christine Utter, Principal Financial Officer & Treasurer (Age 40)
- Mr. Marcio Souza, Chief Operating Officer (Age 39)
- Dr. Neil Almstead, Exec. VP of Research, Pharmaceutical Operations & Technology (Age 51)
Who are PTC Therapeutics' major shareholders?
PTC Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional investors include Boston Advisors LLC (0.05%). Company insiders that own PTC Therapeutics stock include Christine Marie Utter, Dawn Svoronos, Marcio Souza, Neil Gregory Almstead and Stuart Walter Peltz. View Institutional Ownership Trends for PTC Therapeutics.
Which major investors are buying PTC Therapeutics stock?
How do I buy shares of PTC Therapeutics?
Shares of PTCT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is PTC Therapeutics' stock price today?
One share of PTCT stock can currently be purchased for approximately $34.87.
How big of a company is PTC Therapeutics?
PTC Therapeutics has a market capitalization of $1.76 billion and generates $194.39 million in revenue each year. The biopharmaceutical company earns $-79,000,000.00 in net income (profit) each year or ($2.02) on an earnings per share basis. PTC Therapeutics employs 373 workers across the globe.
What is PTC Therapeutics' official website?
How can I contact PTC Therapeutics?
PTC Therapeutics' mailing address is 100 CORPORATE COURT, SOUTH PLAINFIELD NJ, 07080. The biopharmaceutical company can be reached via phone at 908-222-7000 or via email at [email protected]
MarketBeat Community Rating for PTC Therapeutics (NASDAQ PTCT)
MarketBeat's community ratings are surveys of what our community members think about PTC Therapeutics and other stocks. Vote "Outperform" if you believe PTCT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PTCT will underperform the S&P 500 over the long term. You may vote once every thirty days.
